Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.

about

Standing in the Shifting Sands of Molecular Targeting and Precision Medicine Is the Oasis of 21st-Century Oncology Therapeutics.

P2860

Q50045474-89AAE97D-14B7-4B6B-9DF8-05C21B8D8B22

P2860

Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.

Item

http://www.wikidata.org/entity/Q47969048

description

2017 nî lūn-bûn

@nan

2017 թվականի հոկտեմբերին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

name

Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.

@en

Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.

@nl

type

Item

label

Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.

@en

Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.

@nl

prefLabel

Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.

@en

Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.

@nl

P1476

Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.

@en

P2093

Catherine J Lucas

http://www.w3.org/2001/XMLSchema#string

Jennifer H Martin

http://www.w3.org/2001/XMLSchema#string

P2860

The impact of comorbidity on cancer and its treatment

Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

P304

S78-S98

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.937

http://www.w3.org/2001/XMLSchema#string

P478

57 Suppl 10

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28921641

http://www.w3.org/2001/XMLSchema#string

Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.

about

P2860

P2860

Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698